We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. Supreme Court refused to hear appeals brought by Purdue Pharma LP for a patent infringement case centered on reformulations of the painkiller OxyContin, clearing several barriers to the development of generics. Read More
Spanish drugmaker Grifols is accused of defrauding the government of millions of dollars for promoting the use of its antithrombin drug, Thrombate III, in unapproved indications. Read More
The U.S. solicitor general has urged the Supreme Court to review a Federal Circuit decision that requires biosimilar makers wait six months after receiving FDA approval to launch a product. Read More
UK’s antitrust regulator has charged Pfizer and Flynn Pharma a fine totaling more than $100 million for hiking the prices of their phenytoin sodium capsules for epilepsy. Read More
Global drug spending will climb to $1.5 trillion in the next five years, marking a nearly 32 percent increase, fueled largely by new medicines and emerging markets. Read More
The U.S. government and life sciences industry groups have asked Japan not to change the country’s drug pricing system to annual price reviews and cuts, instead of the current every-two-year review. Read More
Eli Lilly has filed its tenth lawsuit against a drugmaker in the U.S. District Court for the Eastern District of Virginia, alleging infringement of a patent that covers its erectile dysfunction drug Cialis. Read More
Prescription drug spending rose 9 percent to $324.6 billion in 2015, outpacing national health expenditures in all other sectors, according to the Centers for Medicare & Medicaid Services. Read More
Five generics drugmakers are facing a class action lawsuit for allegedly colluding to inflate the price of a historically affordable generic anticonvulsant by more than 500 percent. Read More